Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

392 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the immune responses of UK infants after one or two doses of pneumococcal conjugate vaccine or one or two doses of three different types of meningococcal conjugate vaccine given at either two and three or two and four months of age.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants

NCT00197769

Streptococcus Pneumoniae

COMPLETED PHASE2

Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months

NCT01425372

Streptococcus Pneumoniae

COMPLETED

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

NCT00475033

Vaccines, Pneumococcal Conjugate Vaccine

COMPLETED PHASE3

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

NCT00384059

Vaccines, Pneumococcal

COMPLETED PHASE3

Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants

NCT02918708

Vaccination Immunization

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumococcal Infections Meningococcal Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Intervention Type BIOLOGICAL

men C conjugate vaccine

men C conjugate vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent obtained from parent or legal guardian of infant
* Age 7-11 weeks at first dose

Exclusion Criteria

* Any contraindications to vaccination as specified in the UK Handbook "Immunisation Against Infectious Disease" (Ed 1996)
* \< 7 weeks or \> 11 weeks at first dose

Minimum Eligible Age

7 Weeks

Maximum Eligible Age

11 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes